
ZielBio: An early-stage biotech firm innovating patient outcomes through novel drug discovery.
Founded as an early-stage biotechnology company, ZielBio focuses on identifying novel high-value disease targets and developing therapeutic interventions to improve patient outcomes. The company's core mission is to reimagine drug discovery through its proprietary platform, Zielfind, which combines functional, high-throughput screening with large content data analysis. ZielBio aims to develop new therapeutic modalities that can significantly impact how diseases are treated, ultimately enhancing the quality of life for patients.
ZielBio has attracted notable investors and industry experts who support its innovative approach to drug discovery. The company has achieved key milestones in identifying druggable and specific targets that hold the potential to revolutionize disease treatment. Through its groundbreaking technology and dedicated research, ZielBio has made a significant impact in the biotechnology sector, positioning itself as a leader in the development of novel therapies aimed at improving patient outcomes.

Unravel Biosciences
unravel.bio

Pepper Bio
pepper.bio

BridGene Biosciences

Curie.Bio
curie.bio

Triana Biomedicines
trianabio.com
TigerGene

Rezo Therapeutics
rezotx.com

Reactive Biosciences
reactivebio.com

Actio Biosciences
actiobio.com

Algen Biotechnologies
algenbio.com

Design Pharmaceuticals

BlueLight Therapeutics
bluelighttx.com

Greenstone Biosciences

Zephyr AI
zephyrai.bio

Flexomics
flexomics.com
Companies similar to ZielBio include Unravel Biosciences, Pepper Bio, BridGene Biosciences and Curie.Bio.
ZielBio was founded in 2011.
ZielBio's headquarters is located in Charlottesville, VA, US.
ZielBio's most recent funding round was for $7.5M (USD) in September 2022.
As of Sep 27, 2022, ZielBio has raised a total of $33M (USD).
ZielBio has 13 employees as of Feb 5, 2024.